TALPHERA, INC. (TLPH)
About TALPHERA, INC.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2018
- $2.2M
- Net income
- -$14.3M
- Total assets
- $29.7M
- Market cap
- $70.1M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $70.1M
- Shares outstanding
- 64.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 11, 2011
Talphera, Inc. (TLPH) Stock Price
- Reported a net loss of $14.3M in FY2018.
- Trading 27% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TALPHERA, INC..
Write a review
News about TALPHERA, INC.
News & sentiment via Polygon.io
Talphera, Inc.: frequently asked questions
Is Talphera, Inc. an American company?
Talphera, Inc. is a US-based company headquartered in San Mateo, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Talphera, Inc. headquartered?
Talphera, Inc. is headquartered in San Mateo, California, United States.
Is Talphera, Inc. publicly traded?
Yes — Talphera, Inc. is a publicly traded company. Its stock trades under the ticker symbol TLPH on the NASDAQ.
What does Talphera, Inc. do?
Talphera, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
